Article Text

Download PDFPDF
CASE REPORT
False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use
  1. T Michael Farley1,2,
  2. Emily N Anderson1,
  3. Jade N Feller1
  1. 1Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa, USA
  2. 2Department of Pharmacy, Mercy Hospital, Iowa, USA
  1. Correspondence to Dr T Michael Farley, mike-farley{at}uiowa.edu

Summary

We report a likely false-positive phencyclidine (PCP) result detected with a urine drug screen (UDS) (Medtox, St Paul, Minnesota, USA) in the setting of therapeutic desvenlafaxine (Pristiq) use. Desvenlafaxine (O-desmethylvenlafaxine) is the active metabolite of venlafaxine (Effexor). Prior reports have confirmed venlafaxine use resulting in a false-positive for PCP on a UDS. However, there has been a paucity of reporting of commercially available desvenlafaxine formulations (Pristiq, Khedezla) resulting in false-positives for PCP on a UDS.

  • psychiatry (drugs and medicines)
  • general practice / family medicine
  • drug misuse (including addiction)
  • toxicology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Conception or design: TMF. Analysis or interpretation of data: TMF, JNF, ENA. Drafting the work and revisions: TMF, JNF, ENA. Final approval of the version published: TMF, JNF, ENA. All authors made substantial contributions to this work. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.